跳至主要内容
临床试验/NCT05719285
NCT05719285已完成4 期

Single-Dose Versus Multi-Dose Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

The Cleveland Clinic1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年12月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
100
试验地点
1
主要终点
Establish Noninferiority of the Single Dose Antibiotic Administration to the Multi-dose Antibiotic Administration.

研究概览

简要总结

The goal of this clinical trial is to evaluate the outcomes of differing durations of antibiotic prophylaxis with bladder onabotulinumtoxinA injection in patients with refractory overactive bladder.

The main question it aims to answer are:

• Is the incidence of post-procedure UTI similar between single-dose and multi-day durations of peri-procedural antibiotics?

Participants will be randomized to single-dose versus multi-day dose of antibiotic prophylaxis with bladder onabotulinumtoxinA injection.

Researchers will compare incidence of UTI in each group to see if there is a significant difference.

详细描述

  • After informed consent is obtained, urinalysis will be collected. Post-void residual will also be assessed by bladder scan if not already documented in the electronic medical record in the prior three months.

  • Patients with positive urinalysis and symptomatic for UTI will be excluded from the study.

  • Patients will be randomized in a 1:1 ratio to one of two groups.

  • Group 1 will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.

  • Group 2 will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.

  • The same antibiotic will be continued for 3 days of total antibiotic administration with additional doses prescribed to the patient's pharmacy.

  • Bladder onabotulinumtoxinA injection and dosing will be completed based on the surgeon's standard technique and template.

  • Bladder onabotulinumtoxinA injection will be completed by staff or fellows in the Female Pelvic Medicine and Reconstructive Surgery division of the Genitourinary and Kidney Institute.

  • Patients will be followed for 4 weeks after the procedure.

  • At 4 weeks study investigators will contact the patient by phone to evaluate for any UTIs or adverse events not previously reported by the patient during the study period.

  • Chart review will occur at 4 weeks to assess for any unreported events.

  • Other than this additional phone call, post-operative patient management will not deviate from the standard of care.

  • Patients will be instructed to report symptomatic UTIs, urinary retention, or any other adverse events related to onabotulinumtoxinA or antibiotic to investigators.

  • Patients that report symptoms suggestive of a UTI will result in obtaining a urine culture.

  • Symptomatic, culture proven UTIs will be treated with appropriate antibiotics per the current AUA guidelines.

  • Symptoms suggestive of urinary retention, such as increased urinary frequency, voiding small amounts of urine, or feelings of incomplete bladder emptying, will result in obtaining a post void residual (PVR) and urinalysis.

  • Patients will undergo teaching to perform self, clean intermittent catheterization of the bladder per the discretion of the operating surgeon.

  • Any adverse reactions to the prescribed antibiotic will result in discontinuation of the antibiotic and managed according to the severity of the reaction.

Antibiotic regimens:

Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.

First line:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants with planned in-office bladder onabotulinumtoxinA injection
  • Men or Women Age ≥ 18
  • Able to read, speak, and write in English
  • No contraindication to injection of onabotulinumtoxinA - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation
  • Willingness and ability to initiate intermittent catheterization post-treatment if required
  • No contraindication to oral antibiotics
  • No active antibiotic therapy for any indication at the time of onabotulinumtoxinA injection
  • Have not participated in this study before

排除标准

  • Any type of catheterization to empty the bladder
  • Unwillingness or inability to initiate intermittent catheterization post-treatment if required
  • Less than 3 months since last bladder onabotulinumtoxinA injection
  • Pregnant and/or breastfeeding
  • Active symptomatic UTI the day of the procedure - new or worsening frequency, urgency, dysuria, hematuria, suprapubic/flank pain, fevers or chills
  • History of recurrent UTI
  • Prior development of urinary retention or incomplete bladder emptying after bladder onabotulinumtoxinA injection requiring catheterization of any type

研究组 & 干预措施

1: Single-Dose Antibiotic Prophylaxis

Active Comparator

Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection.

干预措施: Single-Dose Antibiotic (Drug)

2: Multi-Dose Antibiotic Prophylaxis

Active Comparator

Patients will receive one dose of antibiotic prior to bladder onabotulinumtoxinA injection. The same antibiotic will be continued for 3 days of total antibiotic administration with additional doses prescribed to the patient's pharmacy.

干预措施: Multi-Dose Antibiotic (Drug)

结局指标

主要结局

Establish Noninferiority of the Single Dose Antibiotic Administration to the Multi-dose Antibiotic Administration.

时间窗: 4 weeks

To assess this aim, the rate of postoperative urinary tract infection (UTI) within 4 weeks following bladder onabotulinumtoxinA injection will be compared between groups. Noninferiority will be declared if the incidence of UTI in the single dose group is not more than UTI incidence in the multiple dose group within statistical variability, by the prespecified noninferiority margin.

次要结局

  • Antibiotic Adverse Events(4 weeks)
  • Symptomatic Urinary Retention(4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验